Identifying Correlates of Brain Microglial Activation in Neuropsychiatric Syndromes: a Dimensional Approach
NCT03705715
Recruiting
The purpose of this research is to determine whether there is more extensive inflammation in the brain of people with clinical evidence of neuropsychiatric syndromes, such as mood disorder, chronic pain syndrome, dementia, traumatic brain injury, or substance abuse. The research will also explore whether there is more inflammation in patients with more neuropsychiatric symptoms. Inflammation in the brain will identified by using Positron Emission Tomography (PET) with the radiotracer \[11C\]PBR-... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/14/2025
Locations: BBSB at UTHealth, Houston, Texas
Conditions: Neuropsychiatric Syndromes
Register for Updates
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
NCT03802695
Recruiting
This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation for hematologic malignancies.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/14/2025
Locations: City of Hope, Duarte, California +7 locations
Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia, Myelofibrosis, Chronic Myeloid Leukemia
Register for Updates
The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant
NCT03805789
Recruiting
This study is a phase 2 / 3 prospective, double-blind, randomized, multicenter, placebo-controlled study for prevention of acute GVHD (aGVHD) in participants undergoing an unrelated (matched or single allele mismatched) or matched related allogeneic hematopoietic cell transplantation (HCT).
Gender:
ALL
Ages:
12 years and above
Trial Updated:
03/14/2025
Locations: HonorHealth Scottsdale Shea Medical Center, Scottsdale, Arizona +33 locations
Conditions: Acute-graft-versus-host Disease
Register for Updates
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
NCT03894917
Recruiting
This is an observational, prospective cohort study that will recruit a diverse sample of 84 participants with newly diagnosed with unresectable, advanced hepatocellular carcinoma (HCC) at the UT Health Cancer Center in San Antonio. This study uses geriatric assessment tools with participants 65 years and older and collects adverse events and exploratory markers of aging for all participants.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Mays Cancer Center, San Antonio, Texas
Conditions: Carcinoma, Hepatocellular
Register for Updates
PAIN: a Project Assessing the Impact of a Novel Cannabinoid Product
NCT03984565
Recruiting
This study is a clinical trial of a high-cannabidiol (CBD) sublingual product compared to placebo for 9 weeks in patients with chronic pain conditions. The study will assess the impact of CBD on chronic pain symptoms, conventional medication use, clinical state, quality of life, cognition, and biomarkers.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
03/14/2025
Locations: McLean Hospital, Belmont, Massachusetts
Conditions: Chronic Pain
Register for Updates
Animal and Plant Proteins and Glucose Metabolism
NCT03994367
Recruiting
The goal of this proposal is to determine the effect of a high protein diet in which the increase in protein intake is derived from different sources (animal vs plant and protein-rich whole foods vs protein isolates) on: i) liver and muscle insulin sensitivity; ii) the metabolic response to a meal, and iii) 24-h plasma concentration profiles of glucose, glucoregulatory hormones, and protein-derived metabolites purported to cause metabolic dysfunction.
Gender:
ALL
Ages:
Between 21 years and 70 years
Trial Updated:
03/14/2025
Locations: University of Missouri School of Medicine, Columbia, Missouri
Conditions: Metabolic Syndrome, Metabolic Syndrome, Protection Against, Glucose Metabolism Disorders
Register for Updates
Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms
NCT04141020
Recruiting
The objective of this study is to explore the effects of Sirolimus on the underlying molecular alterations of cerebral aneurysms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: University of Miami, Miami, Florida
Conditions: Cerebral Aneurysm
Register for Updates
Study of DF1001 in Patients with Advanced Solid Tumors
NCT04143711
Recruiting
DF1001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase will be a dose escalation phase, enrolling patients with various types of solid tumors that express human epidermal growth factor receptor 2 (HER2). The second phase will include a dose expansion using the best dose selected from the first phase of the study. Multiple cohorts will be opened with eli... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: University of California Irvine Medical Center, Irvine, California +51 locations
Conditions: Solid Tumor, Adult
Register for Updates
Duke APOL1 Research Biorepository
NCT04160507
Recruiting
The Duke ApoL1 Nephropathy Biorepository aims to address needs within non-diabetic kidney failure research by utilizing existing and, when necessary, developing new infrastructure to support the consent of patients and the collection of dedicated samples for ApoL1 Nephropathy biorepository. The mutations in ApoL1 gene that are strongly associated with kidney disease are only present in individuals of recent African ancestry (i.e., black people). Caucasians do not have these ApoL1 mutations nor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: End Stage Kidney Disease
Register for Updates
Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery
NCT04169763
Recruiting
This phase I trial studies the side effects and best dose of nelfinavir when given together with cisplatin and external beam radiation therapy in treating patients with vulvar cancer that has spread to nearby tissue or lymph nodes (locally advanced) and cannot be removed by surgery. Nelfinavir is an antiviral drug normally used to treat human immunodeficiency virus (HIV). Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Stage II Vulvar Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8, Stage IIIA Vulvar Cancer AJCC v8, Stage IIIB Vulvar Cancer AJCC v8, Stage IIIC Vulvar Cancer AJCC v8, Stage IVA Vulvar Cancer AJCC v8
Register for Updates
Effect of CPAP on 6-Minute Walk Test Outcomes in Patients with ECAC
NCT04217603
Recruiting
The purpose of this protocol is to perform a prospective, randomized, double-blinded, pacebo-controlled clinical trial to determine the influence of a non-invasive positive pressure ventilation device on exercise capacity and symptoms in adult patients with ECAC. Primary outcome will include the total distance traversed by the study subject during a standard 6-minute walk test, and secondary outcomes will include peak flow measurement and symptom reporting before and after the exercise testing.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Tracheobronchomalacia, Excessive Dynamic Airway Collapse
Register for Updates
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
NCT04379596
Recruiting
DESTINY-Gastric03 will investigate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of trastuzumab deruxtecan (T-DXd) alone or in combination with chemotherapy and/or immunotherapy in HER2-expressing advanced/metastatic gastric/gastroesophageal junction (GEJ) and esophageal adenocarcinoma patients. Study hypotheses: Combination of T-DXd with cytotoxic chemotherapy and/or immunotherapy administered to subjects at the recommended phase 2 dose will sho... Read More
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
03/14/2025
Locations: Research Site, Santa Monica, California +99 locations
Conditions: Gastric Cancer
Register for Updates